Cowen And Company, LLC Mirati Therapeutics, Inc. Call Options Transaction History

Cowen And Company, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $4.01 Million - $5.78 Million	-30,400 Reduced 57.79%	22,200 $21,000
Q3 2021 Nov 12, 2021	BUY	$132.13 - $177.45 $6.95 Million - $9.33 Million	52,600 New	52,600 $232,000
Q2 2021 Aug 13, 2021	SELL	$144.0 - $179.73 $1.94 Million - $2.43 Million	-13,500 Closed	0 $0
Q1 2021 May 04, 2021	SELL	$158.92 - $221.61 $7.33 Million - $10.2 Million	-46,100 Reduced 77.35%	13,500 $42,000
Q4 2020 Feb 08, 2021	BUY	$162.05 - $240.27 $8.8 Million - $13 Million	54,300 Added 1024.53%	59,600 $430,000
Q3 2020 Nov 03, 2020	SELL	$113.26 - $167.27 $532,322 - $786,169	-4,700 Reduced 47.0%	5,300 $85,000
Q2 2020 Aug 13, 2020	SELL	$72.01 - $120.39 $1.3 Million - $2.17 Million	-18,000 Reduced 64.29%	10,000 $43,000
Q1 2020 May 11, 2020	BUY	$69.78 - $116.21 $1.74 Million - $2.91 Million	25,000 Added 833.33%	28,000 $80,000
Q4 2019 Feb 11, 2020	BUY	$70.76 - $128.86 $212,280 - $386,580	3,000 New	3,000 $59,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Cowen And Company, LLC with notifications on news.